Navigation Links
Drug Effective Against Heart-Lung Disorder
Date:6/19/2008

Bosentan slowed decline linked to pulmonary arterial hypertension, study found

THURSDAY, June 19 (HealthDay News) -- The drug bosentan reduced clinical decline in patients with early-stage pulmonary arterial hypertension (PAH), Italian researchers report.

PAH is a progressive disease in which increased pulmonary resistance in the lungs causes structural damage to the heart, eventually leading to heart failure and death.

Previous studies have shown that bosentan improves exercise capacity and pulmonary vascular resistance (PVR) and slows clinical decline in patients with later stages of PAH.

This new study included 185 people, ages 12 and over, with early-stage PAH who were divided into two groups. One group received bosentan, and the other group received a placebo. The patients' PVR and distance they could walk in six minutes were measured at the start of the study and again six months later.

After six months, the mean PVR improved at a significant rate for those on bosentan versus those on placebo, wrote Professor Nazzareno Galie, of the Institute of Cardiology at the University of Bologna, and colleagues.

The mean six-minute walk distance also increased 11.2 meters in the bosentan group from 438 meters at baseline, compared to a decrease from 431 meters to 423 meters in the placebo group. However, these changes in distance weren't clinically significant.

Three percent of patients in the bosentan group and 14 percent of those in the placebo group experienced clinical worsening events, such as symptomatic progression of PAH, hospitalization and death. This difference was statistically significant.

Thirteen percent of patients in the bosentan group and 9 percent of those in the placebo group reported serious adverse events. Fainting was the most common adverse event in the bosentan group, and right ventricular failure was the most common in the placebo group.

The findings are in the June 21 issue of The Lancet.

"This study broadens the potential for bosentan as a treatment in pulmonary arterial hypertension, and the evidence presented by (the researchers) should soon be translated into clinical practice," Dr. Neeraj Dhaun and Professor David Webb, Queen's Medical Research Institute, University of Edinburgh, U.K., wrote in an accompanying comment.

More information

The U.S. National Heart, Lung, and Blood Institute has more about PAH.



-- Robert Preidt



SOURCE: The Lancet, news release, June 20, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Build and Maintain an Effective Competitive Intelligence Group
2. Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey
3. HIV Tests Cost-Effective for Some Seniors
4. Effective health messages may yield vaccine compliance among ER workers
5. Effective treatment for sickle cell underused by doctors
6. Effective Communication of Clinical Studies for Maximum Impact
7. Winning Method - Effective Identification and Development of Clinical Investigators
8. Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
9. Hand bone mineral density is an effective predictor of mortality in rheumatoid arthritis
10. Whole Milk Cheaper, Effective Contrast Agent for GI Scans
11. Tracking Cancer Drugs Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Effective Against Heart-Lung Disorder
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: